Vanguard Capital Management
IMMX icon

Vanguard Capital Management’s Immix Biopharma IMMX Stock Holding History

Vanguard Capital Management’s Portfolio IMMX Stock Details IMMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$25.8M Buy
2,507,122
+719,128
+40% +$6.67M ﹤0.01% 2306
2026
Q1 		$16.3M Buy
+1,787,994
New +$13.1M ﹤0.01% 2456

Other funds holding IMMX

JT
Jupiter Topco New York $245B AUM
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Vanguard Capital Management's IMMX Position: Q2 2026 in Review

Vanguard Capital Management increased its Immix Biopharma (IMMX) stake by 40% in Q2 2026, buying an estimated $6.67M and bringing the position to 2,507,122 shares worth $25.8M. The position accounts for ﹤0.01% of the portfolio, ranked #2306.

Vanguard Capital Management first reported a position in IMMX in Q1 2026 and has held it in 2 quarters since. 109 funds tracked by Wall St. Rank hold IMMX as of Q2 2026.

  • Vanguard Capital Management held 2,507,122 shares of Immix Biopharma worth $25.8M as of Q2 2026.
  • Vanguard Capital Management bought 719,128 Immix Biopharma shares in Q2 2026, an estimated $6.67M.
  • Immix Biopharma made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #2306 holding.
  • Vanguard Capital Management first reported a position in Immix Biopharma in Q1 2026 and has held it in 2 quarters since.
  • 109 funds tracked by Wall St. Rank held Immix Biopharma as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.